Antitumor activity of filtrate of a novel Staphylococcus aureus with incomplete hemolytic phenotype
10.13200/j.cnki.cjb.004477
- VernacularTitle:新型不完全溶血表型金黄色葡萄球菌滤液的抗肿瘤活性
- Author:
LI Xinyu
- Publication Type:Journal Article
- Keywords:
Staphylococcus aureus;
Hemolytic phenotype;
Filtrate;
Tumor;
Cytotoxicity
- From:
Chinese Journal of Biologicals
2025;38(05):557-561+568
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the antitumor activity of the filtrate of a novel Staphylococcus aureus with incompletehemolytic phenotype(SIHP), and to provide references for screening new antitumor drugs.MethodsThe epidemiologicalcharacteristics of the novel SIHP were summarized and analyzed. The hemolytic phenotypes of the novel SIHP, classic Staphy-lococcus aureus with complete hemolytic phenotype(SCHP) and quality control strains ATCC29213 and ATCC25923 weredetected on blood agar plate(BAP) by three-point method. Staphylococcus aureus filtrate was prepared by inoculating LBbroth, centrifuging and filtering after fermentation. The Staphylococcus aureus filtrate and its diluents with RPMI1640 ofdifferent volume fractions(1∶1, 1∶3, 1∶7) were co-incubated with human non-small cell lung cancer HCC827 cells, themorphological changes were observed, and the cells were classified and counted under a microscope.ResultsThe clinicalspecimen isolation rate of the novel SIHP was only 2. 01%, and its hemolytic phenotype on BAP was unique with strongrecognition. Compared with the classical SCHP and quality control strain ATCC25923, the novel SIHP filtrate showed signifi-cantly stronger tumor cytotoxicity, and damaged HCC827 cells in a concentration-dependent manner, leading to the release of cell contents, balloon-like degeneration of cell membrane or bare nucleus-like degeneration of cells.ConclusionThe novel SIHP may be a new subspecies of Staphylococcus aureus with a unique genetic background, and the filtrate contains highly effective antitumor active substances, which can provide a material basis for the screening of new antitumor drugs.
